Yusuke Nakata1,2, Nobuhiro Hanai1, Daisuke Nishikawa1, Hidenori Suzuki1, Yusuke Koide1, Yujiro Fukuda1, Motoo Nomura3, Takeshi Kodaira4, Takeshi Shimizu2, Yasuhisa Hasegawa5. 1. Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. 2. Department of Otorhinolaryngology, Shiga University of Medical Science, Otsu, Shiga, 520-2192, Japan. 3. Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan. 4. Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan. 5. Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. hasegawa@aichi-cc.jp.
Abstract
BACKGROUD: Laryngeal preservation is an important consideration when treating cervical esophageal cancers (CECs) such as laryngeal cancer. The standard treatment for CEC allowing laryngeal preservation is chemoradiotherapy. However, in cases of laryngeal cancer, chemoselection has also been applied as a treatment strategy that promotes larynx preservation. This strategy involves assigning the appropriate radical treatment according to the primary tumor's response to induction chemotherapy. Since there have been no studies of the application of chemoselection in CEC cases, the present study compared the results, including laryngeal preservation rates, obtained upon applying chemoselection and chemoradiotherapy to CEC. STUDY DESIGN: This was a retrospective cohort study of cervical esophageal squamous cell carcinoma patients treated using chemoselection or chemoradiotherapy at Aichi Cancer Center Hospital between January 2000 and March 2013. A total of 42 patients were enrolled. RESULTS: The 2-year overall survival and laryngeal preservation rates for the chemoselection group versus the primary radiotherapy group were 65.1 and 57.3 versus 40 and 83.3%, respectively (P = 0.017 and P = 0.122, respectively). The 2-year locoregional control rates for the chemoselection and primary radiotherapy groups were 68 and 25%, respectively (P = 0.045). CONCLUSION: The chemoselection group achieved favorable results. Therefore, chemoselection can be applied as a treatment strategy for CEC.
BACKGROUD: Laryngeal preservation is an important consideration when treating cervical esophageal cancers (CECs) such as laryngeal cancer. The standard treatment for CEC allowing laryngeal preservation is chemoradiotherapy. However, in cases of laryngeal cancer, chemoselection has also been applied as a treatment strategy that promotes larynx preservation. This strategy involves assigning the appropriate radical treatment according to the primary tumor's response to induction chemotherapy. Since there have been no studies of the application of chemoselection in CEC cases, the present study compared the results, including laryngeal preservation rates, obtained upon applying chemoselection and chemoradiotherapy to CEC. STUDY DESIGN: This was a retrospective cohort study of cervical esophageal squamous cell carcinoma patients treated using chemoselection or chemoradiotherapy at Aichi Cancer Center Hospital between January 2000 and March 2013. A total of 42 patients were enrolled. RESULTS: The 2-year overall survival and laryngeal preservation rates for the chemoselection group versus the primary radiotherapy group were 65.1 and 57.3 versus 40 and 83.3%, respectively (P = 0.017 and P = 0.122, respectively). The 2-year locoregional control rates for the chemoselection and primary radiotherapy groups were 68 and 25%, respectively (P = 0.045). CONCLUSION: The chemoselection group achieved favorable results. Therefore, chemoselection can be applied as a treatment strategy for CEC.
Authors: Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson Journal: N Engl J Med Date: 1991-06-13 Impact factor: 91.245
Authors: Jeffrey M Vainshtein; Vivian F Wu; Matthew E Spector; Carol R Bradford; Gregory T Wolf; Francis P Worden Journal: Expert Rev Anticancer Ther Date: 2013-09 Impact factor: 4.512
Authors: Cai Neng Cao; Jing Wei Luo; Li Gao; Guo Zhen Xu; Jun Lin Yi; Xiao Dong Huang; Su Yan Li; Jian Ping Xiao; Shao Yan Liu; Zhen Gang Xu; Ping Zhang Tang Journal: JAMA Otolaryngol Head Neck Surg Date: 2014-10 Impact factor: 6.223
Authors: Susan Urba; Gregory Wolf; Avraham Eisbruch; Francis Worden; Julia Lee; Carol Bradford; Theodoros Teknos; Douglas Chepeha; Mark Prince; Norman Hogikyan; Jeremy Taylor Journal: J Clin Oncol Date: 2005-12-27 Impact factor: 44.544
Authors: Francis P Worden; Jeffrey Moyer; Julia S Lee; Jeremy M G Taylor; Susan G Urba; Avraham Eisbruch; Theodoros N Teknos; Douglas B Chepeha; Mark E Prince; Norman Hogikyan; Amy Anne D Lassig; Kevin Emerick; Suresh Mukherji; Lubomir Hadjiski; Christina I Tsien; Tamara H Miller; Nancy E Wallace; Heidi L Mason; Carol R Bradford; Gregory T Wolf Journal: Laryngoscope Date: 2009-08 Impact factor: 3.325
Authors: Armando De Virgilio; Andrea Costantino; Carlo Castoro; Giuseppe Spriano; Bianca Maria Festa; Giuseppe Mercante; Davide Franceschini; Ciro Franzese; Marta Scorsetti; Andrea Marrari; Raffaele Cavina; Salvatore Marano Journal: J Cancer Res Clin Oncol Date: 2022-03-02 Impact factor: 4.553